摘要
目的:研究常规剂量重组人促红细胞生成素(rHuEPO)治疗慢性肾脏病(CKD)贫血的有效性和安全性。方法:233例CKD贫血患者按照治疗前血红蛋白(Hbg)值分为3个组,应用rHuEPO治疗12wk后,比较各组应用前后血象变化,并评价其有效性和安全性。结果:全部患者完成疗程,总显效率为52.8%,总有效率为96.1%,治疗前后各组Hbg值比较有显著性差异(P<0.01)。结论:rHuEPO可有效治疗CKD贫血,改善肾脏功能及多项实验室指标,是临床上改善CKD贫血一种安全、有效的治疗措施。
OBJECTIVE： To study the clinical efficacy and safety of rHuEPO in the treatment of chronic kidney disease （CKD） .METHODS： 233 cases with chronic kidney disease were divided into 3 groups according to patients＇ baseline Hbg level and were treated with rHuEPO for 12 weeks.The levels of Hbg before and after treatment were compared among groups, and the efficacy and safety of rHuEPO were evaluated.RESULTS： All the patients had completed course of treatment.The total excellent effective rate was 52.8% and total effective rate was 96.1% .There were significant differences among groups in Hbg level before and after treatment（P〈0.01） .CONCLUSION： γHuEPO was effective and safe for CKD anemia and it can improve renal function and laboratory data.
出处
《中国药房》
CAS
CSCD
北大核心
2007年第26期2040-2041,共2页
China Pharmacy
